UPPSALA, Sweden, Feb. 11, 2005 (PRIMEZONE) -- Q-Med:
- Turnover during 2004 rose by 36 percent to SEK 823.2 (607.4) million.
- Operating income amounted to SEK 339.4 (821.0) million.
- Operating income adjusted for one-time revenues and costs attributable to legal action in USA amounted to SEK 25.5 (-20.1) million.
- Net income after tax amounted to SEK 263.2 (845.3) million for the year.
- Earnings per share amounted to SEK 10.61 (34.06).
- Good sales growth within all product areas. Strong increase within the Hospital Healthcare product area, 60 percent.
- More than 1.5 million syringes have been sold during the year, which is more than double the number sold the previous year.
- The Board proposes a regular dividend of SEK 3 per share and an extraordinary dividend of SEK 5 per share.
Queries should be addressed to:
Bengt Agerup, President and CEO, Tel: +46 70-974 90 25.
Erika Kjellberg Eriksson, Vice President and CFO, Tel: + 46 70-974 90 20.
Anne Rhenman, Director Investor Relations and Corporate Communications, Tel: +46 70-974 90 15
Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces, markets and sells medical implants. All products are based on the company's patented NASHA technology - Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Q-Med today has approximately 540 employees, with approximately 350 at the company's head office and production facility in Uppsala. The Q-Med share is listed on the O- list, Attract 40 of the Stockholm Stock Exchange.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=71398&fn=wkr0001.pdf
The full report